 SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 GLOBE NEWSWIRE -- Satsuma Pharmaceuticals, Inc. Nasdaq: STSA, a clinical-stage biopharmaceutical company developing STS101 dihydroergotamine DHE nasal powder, a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference and invites investors to participate via webcast. Please see additional details below: 